Cash-rich and product-poor pharmaceutical firms playing catch-up in large molecules have turned 2006 into a bumper year for dealmaking. Even so, Genmab AS's monster December deal with GSK for worldwide rights to the Phase III anti-CD20 antibody ofatumumab (HuMax-CD20), which includes a whopping $459 million in up-front cash and equity payments, seemed to catch analysts by surprise, beating even optimistic expectations
Christopher Morrison
Cash-rich and product-poor pharmaceutical firms playing catch-up in large molecules have turned 2006 into a bumper year for dealmaking. Not...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
